Vaccines – Randy Bock MD PC

In May 2026, a wildlife expedition cruise ship called the MV Hondius departed Argentina carrying roughly 150 passengers bound for Antarctica. Within days, a handful of travelers who had hiked in rodent-inhabited mountain terrain fell gravely ill. By the time the ship made port, two had died, a third death was suspected, and eleven passengers total were linked to the Andes strain of hantavirus — the only hantavirus known to transmit person to person.

It should have been a regional public health notice. Instead, it became a global media event.

Warships were dispatched to remote Atlantic islands. Biocontainment units across three continents activated. Wire services led with breathless dispatches for days. And social media lit up with one burning question: Is this the next COVID?

In a recent interview, Dr. David Bell — physician, epidemiologist, former WHO staffer of nine years, and one of the more outspoken critics of the global pandemic-preparedness industrial complex — offered a very different question: Who benefits from the panic?

• What Is Hantavirus — and How Serious Is the 2026 Outbreak, Really?
• A Pattern Worth Recognizing: The Outbreak Carousel
• The WHO Pandemic Treaty: Still Struggling, Still Necessary to Sell
• The mRNA Vaccine Angle: Marketing a Product Without a Market
• How the WHO’s Funding Model Changed Everything
• The Real Cost: What Doesn’t Make the Headlines
• Vaccines as Medicine, Not Mandates
• What Would Actually Help
• The Bottom Line on Hantavirus 2026
• FAQs
  • Q1: Is the hantavirus outbreak 2026 a pandemic risk to the general public?
  • Q2: Why did the 2026 hantavirus outbreak get so much media coverage if it wasn’t a major threat?
  • Q3: What is the WHO pandemic treaty, and why is it controversial?
  • Q4: How does the mRNA hantavirus vaccine connect to the media coverage of the 2026 outbreak?
  • Q5: What does Dr. David Bell recommend instead of pandemic preparedness spending?

Before unpacking the politics, the science deserves a fair hearing.

Hantaviruses spread primarily through inhalation of aerosolized rodent droppings, urine, or saliva. The Andes variant — endemic to South America — is unique in that it can, under conditions of prolonged close contact, spread from person to person. Nurses caring for severely ill patients have contracted it. Household members sharing beds with infected partners have gotten sick. But casual transmission in public settings has never been documented.

The hantavirus outbreak 2026 aboard the MV Hondius produced 8 confirmed cases, 3 more suspected, and 2–3 deaths among 150 people confined together for weeks in the South Atlantic. That is a meaningful but contained cluster — not an exponential spread event.

More telling: population surveys in rural South America show that over 1% of residents — and many people who keep pet mice — carry hantavirus antibodies, meaning they were exposed and their immune systems handled it without hospitalization. The hospitalization fatality rate is high, but that reflects who gets counted, not the full picture of infection. Most exposures appear to be mild or completely silent.

The WHO estimates 10,000–100,000 hantavirus cases occur globally each year, including several thousand in Europe. This is not a new pathogen. It has not mutated into something novel. The genome sequenced from the cruise ship cluster is consistent with a 2018 isolate and shows the expected rate of natural mutation. No lab-origin theory holds water.

So why did it dominate the news cycle for weeks?

Dr. Bell describes what he calls a recurring carousel of “petty plagues” — small outbreaks inflated into existential threats:

Compare these numbers to the diseases that kill people every single day without front-page coverage:

The disparity is not an accident of newsworthiness. It reflects something structural about how the global health agenda is now set — and who funds it.

At the time of the MV Hondius outbreak, the WHO was in the middle of yet another attempt to finalize its pandemic agreement — specifically, the Pathogen Access and Benefit-Sharing (PABS) annex, the section dealing with how countries share disease samples and receive equitable access to resulting vaccines and treatments.

The agreement has been stalling for years. African nations in particular have pushed back, questioning whether signing on delivers genuine equity or merely locks them into a system that funnels public money toward Western pharmaceutical production lines while their own health systems remain underfunded.

For the pandemic preparedness agenda to move forward, the argument needs to feel urgent. Outbreaks that stay in the news help that argument. Outbreaks that quietly resolve in a fishing village in rural Chile do not.

Bell’s pointed observation: once a story is placed with Reuters or AP, it becomes a global story automatically, because virtually every downstream outlet sources from them. The question isn’t why the MV Hondius story ran everywhere. The question is why it was placed prominently enough to run everywhere in the first place.

Here is where the commercial dimension becomes impossible to ignore.

Moderna — the mRNA vaccine company that became a household name during COVID-19 — has been working with a South Korean partner to develop an mRNA-based hantavirus vaccine. The scientific challenge of developing such a vaccine is real. The commercial challenge is more pressing: hantavirus has historically been so rare in public consciousness that there is essentially no demand for a vaccine against it.

Vaccines, as Bell explains, represent an ideal commercial model compared to, say, antibiotics. You give an antibiotic only to someone with a confirmed infection. A vaccine, in theory, goes to everyone — healthy adults, children, elderly — and may require multiple doses, boosters, and eventually mandates to maximize the addressable market. As mRNA technology has matured, the marginal cost of producing a new vaccine from a pathogen’s genetic sequence has dropped dramatically. The bottleneck is no longer manufacturing. It is demand.

Creating demand for a product no one feared requires making people afraid of the underlying disease. A cruise ship outbreak, with its built-in drama of isolation, repatriation flights, biocontainment units, and tearful passengers in hazmat-zone footage, is — at minimum — extremely fortuitous timing.

The WHO that Dr. Bell joined in the 2000s was an institution funded primarily by member states, which gave the secretariat significant discretion over how to allocate resources based on technical need and public health evidence.

That institution no longer exists.

Today, approximately 80% of WHO funding is “specified” — meaning donors earmark it for particular programs. The largest individual donor to the WHO is Bill Gates, who holds substantial private investments in vaccine-related companies and funds. The second largest is GAVI, the vaccine alliance (established around 2001), a public-private partnership whose explicit mandate is to accelerate global vaccine uptake. CEPI — the Coalition for Epidemic Preparedness Innovations, founded in 2017, a century after the Spanish flu — focuses almost entirely on pandemic vaccines and outbreak-response products.

The cumulative result: an institution once tasked with improving health outcomes in low-income countries by fighting malaria, tuberculosis, childhood malnutrition, and sanitation deficits is now substantially organized around emergency outbreak response — the one area most lucrative to pharmaceutical manufacturers.

The proposed budget for pandemic preparedness infrastructure is approximately $31 billion per year — nearly ten times the WHO’s total annual operating budget. The beneficiaries of that spending are overwhelmingly Western pharmaceutical corporations and the global health bureaucracy that orbits them.

Every dollar diverted toward theoretical pandemic preparedness for diseases that infect hundreds — or even thousands — is a dollar not spent on the diseases that kill millions.

COVID-era debt has already produced measurable downstream harm: African nations that borrowed heavily to respond to COVID-19 have since reduced their domestic health spending. Nutrition funding globally has contracted. The number of children dying of malaria is increasing. Tuberculosis case fatality rates are rising as treatment programs are squeezed.

As Bell frames it: the fear machine doesn’t just waste money. It actively makes things worse. Poverty is the primary driver of infectious disease severity. Malnourished children die of MPOX; well-nourished children typically do not. People with healthy immune systems and access to early supportive care survive hantavirus; people without those things often don’t. The pandemic-preparedness industrial complex diverts resources precisely away from the poverty-reduction investments that would do the most to reduce future outbreak mortality — and redirects them toward product pipelines that may never be needed.

It would be reductive to read Bell’s critique as anti-vaccine absolutism. His position is more precise and, arguably, more defensible: vaccines should be evaluated the way any other medicine is evaluated — on an individual cost-benefit basis for the specific patient in front of you.

A newborn in a hepatitis B-negative household in a small North American town does not need a hep-B vaccine on day one of life. A physician working in rural Philippines, where rabies is endemic and post-exposure prophylaxis may be unavailable, should absolutely get vaccinated against rabies. The question is not whether vaccines work. It is whether the mandate-and-mandate-everything model serves public health — or serves revenue targets.

The pandemic treaty, as currently envisioned, would institutionalize the COVID response model globally: mass vaccination campaigns regardless of risk stratification, emergency authorities that override normal regulatory scrutiny, and surveillance infrastructure that benefits the donors who fund it. Bell’s assessment: it will likely do more net harm than good.

The conversation between Bell and host Randy Bock ultimately circles back to something unglamorous and difficult to monetize: economic development.

Hong Kong — a city with no natural resources and an airport famously difficult to land at — became wealthier and healthier than Tanzania, which has fertile land, mineral wealth, beaches, and an educated workforce, because Hong Kong made it possible to start a business in an afternoon. Tanzania, at least historically, burdened entrepreneurs with years of bureaucratic obstacles and corruption at every step.

The same principle applies to global health. Clean water reaches people when economies produce the infrastructure to deliver it. Surgeons wash their hands when hospitals have the equipment and culture to expect it. Malaria kills fewer children when primary care systems can test and treat in the same visit. None of this requires a $31-billion-a-year pandemic preparedness budget. It requires conditions under which countries can build functioning health systems — which begins with debt relief, fair trade, and stopping the deliberate destabilization of resource-rich low-income economies for extraction purposes.

Those are harder problems than sequencing a pathogen and printing an mRNA vaccine. They don’t produce quarterly earnings reports. And they require confronting interests far more powerful than a rodent-borne virus on a cruise ship.

The MV Hondius outbreak was real. The people who died were real tragedies. The Andes hantavirus is a genuine disease that kills people who encounter it without adequate medical support.

It was never going to become a global pandemic. Its own biology — the close-contact requirement, the lack of airborne transmission at scale, the immune clearance that most exposed people experience silently — makes that extremely unlikely. Even WHO epidemiologists said as much during the peak of the media coverage.

What it was — and what Bell argues convincingly — is a case study in how the infrastructure of pandemic fear now operates: which stories get amplified, why certain outbreaks become international incidents while others are ignored, and who stands to benefit when the public believes the next existential pathogen is always just one cruise ship away.

Understanding that machinery isn’t conspiracy thinking. It’s public health literacy.

No. Both the CDC and WHO have confirmed that the overall risk to the general public from the 2026 hantavirus outbreak is extremely low. The Andes virus — the strain involved in the MV Hondius cruise ship cluster — requires prolonged, close physical contact to spread person to person. Unlike COVID-19, it has no demonstrated airborne transmission at scale. Of 150 passengers confined together for weeks on the ship, only 11 cases were confirmed or suspected. Epidemiologists do not expect this outbreak to trigger community spread in any country.

That is exactly the question Dr. David Bell, former WHO adviser, raises in this interview. Hantavirus causes an estimated 10,000–100,000 cases globally every year with little media attention. The MV Hondius outbreak — involving 11 cases and 2–3 deaths — became an international story almost overnight. Bell points to two converging factors: the WHO’s ongoing struggle to finalize its pandemic treaty, which requires sustained public concern about outbreak risk to build political momentum, and the active development of an mRNA hantavirus vaccine by Moderna — a product that needs a fearful public to create market demand.

The WHO Pandemic Agreement is an international framework intended to coordinate global responses to future pandemics, including pathogen sharing, vaccine distribution, and emergency health authorities. The Pathogen Access and Benefit-Sharing (PABS) annex — the most contested section — determines how countries share disease samples and receive equitable access to resulting vaccines and treatments. Critics, including many African nations, argue the treaty disproportionately benefits Western pharmaceutical manufacturers while locking low-income countries into a system that drains resources from proven health interventions like malaria and tuberculosis treatment. As of mid-2026, the PABS annex remains unfinalized.

Moderna has been developing an mRNA-based hantavirus vaccine in partnership with a South Korean research group. The commercial challenge is significant: hantavirus has historically been so obscure that consumer demand for a vaccine against it is essentially nonexistent. mRNA vaccines are most profitable when administered broadly — ideally to entire populations, with boosters, and eventually under mandate. Without public fear of the underlying disease, the return on investment for such a product is extremely difficult to justify. A highly publicized cruise ship outbreak, with repatriation flights and biocontainment footage, provides exactly the kind of visibility that transforms an obscure pathogen into a household concern.

Bell argues that the single most effective investment in global health is economic development in low- and middle-income countries — not emergency outbreak infrastructure. Clean water, functioning primary care systems, nutrition support, and debt relief do more to reduce infectious disease mortality than $31-billion-a-year pandemic preparedness budgets. He points out that people die from diseases like MPOX, malaria, and tuberculosis primarily because of poverty and malnutrition — not because vaccines or surveillance systems are unavailable. The pandemic-preparedness model, in his view, diverts public money toward pharmaceutical production lines while the interventions that would most reduce suffering remain chronically underfunded.

COVID lockdown policy criticism has never been more rigorously or calmly argued than by Jonathan Engler — entrepreneur, legal and medical scholar, co-chair of the UK’s HART Group, and a core contributor to PANDA (Pandemic Data and Analytics). In a wide-ranging interview with Dr. Randy Bock, Engler walks through the evidence, the failures of the contagion model, the mechanics of mass PCR testing, the suppressed science of the nocebo effect, and the broader pattern of medicalization that made the COVID response possible.

This post breaks down his 7 most powerful and evidence-grounded arguments — and why each one deserves serious attention regardless of where you stand on the pandemic debate.

• 1. COVID Lockdown Policy Criticism Begins With a Suppression Strategy That Had No Exit Plan
  • Related Reading
• 2. PANDA and HART: How Organised COVID Lockdown Policy Criticism Saved Children’s Hearts
• 3. PCR Test False Positives: How Mass Testing Manufactured the Pandemic
• 4. The Virus Transmission Model Has a Fundamental Problem That Nobody Is Talking About
• 5. The Nocebo Effect and COVID: The Hidden Mechanism That Public Health Ignored
• 6. Vaccine Mandate for Healthcare Workers: How Organised Dissent Changed UK Policy
• 7. Medicalization and the Expansion of Diagnosis: COVID as a Pattern, Not an Exception
• Key Takeaways: What COVID Lockdown Policy Criticism Actually Demands
• Where to Follow Jonathan Engler
• About This Post

COVID lockdown policy criticism does not begin with conspiracy theories. For Engler, it begins with a single moment in the UK House of Commons when Health Secretary Matt Hancock announced a full national suppression strategy tied explicitly to mass vaccination — with no stated conditions for lifting it otherwise.

Engler had initially accepted the COVID narrative in early 2020, even limiting his family’s social contact. But when the UK government locked itself into an open-ended suppression policy, his confidence collapsed. This wasn’t a balanced public health decision that weighed costs and benefits. It was a policy that had predetermined its own exit conditions before the evidence had a chance to shape them.

This is the entry point of covid lockdown policy criticism at its most principled: not denial of illness, but a demand that policy follow evidence rather than override it. Governments across the world imposed sweeping lockdowns without openly publishing their models for the social, psychological, and economic costs — costs that were, by any serious estimate, enormous.

Engler’s covid lockdown policy criticism was not only theoretical — it was institutional. He joined PANDA (originally Pandemic Data and Analytics, now simply “Panda”) and co-chaired the HART Group alongside Dr. Clare Craig.

HART was a multidisciplinary team of more than 50 professionals — physicians, psychologists, education specialists, economists, and statisticians — who published a weekly newsletter read by tens of thousands of people. Their analyses were actively used by civil society groups across the UK to push back against official policy claims.

Their influence was measurable:

HART was influential enough that the UK Army’s 77th Brigade — a unit associated with information operations and countering domestic disinformation — placed the group under surveillance. A data leak published in The Guardian or The Sunday Times confirmed it. Engler’s response: “We obviously knew we were over the right target.”

For deeper reference on how policy dissent was handled in the UK, see The BMJ’s coverage of scientific censorship during COVID and The Daily Sceptic’s ongoing policy archive.

Central to covid lockdown policy criticism is the argument that the pandemic was not merely detected by testing — it was, to a significant degree, constructed by testing.

Engler’s argument is Bayesian in structure. Before WHO Director-General Tedros issued his famous instruction to “test, test, test,” there was no detectable signal of excess mortality or even excess respiratory illness attendance in healthcare systems anywhere in the world. The moment mass PCR testing began, positive cases appeared in enormous volumes. In New York, roughly 30% of tests were returning positive at certain points.

But this was not evidence of a sudden explosive novel pathogen. It was the predictable consequence of applying a highly sensitive test — with known cross-reactivity to endemic coronaviruses already responsible for roughly one-fifth of common colds — to a population that had never previously been tested for it.

This is what Engler calls PCR test false positives in the context of pandemic construction. He illustrates it memorably: an AI trained to identify living plants will perform brilliantly in Miami, where almost every green, leaf-shaped object is indeed a plant. Put the same AI to work in a New York office building in winter, and a large proportion of its identifications will be fake decorative plants. The test is identical. The background prevalence has changed everything.

Engler, along with colleagues Martin Neil and Norman Fenton — both leading statisticians at Queen Mary University of London — has published extensively on the poor validation of SARS-CoV-2 PCR tests. Fenton has also written on the Bayesian misinterpretation of COVID statistics at probabilityandlaw.blogspot.com.

Covid lockdown policy criticism that engages seriously with the underlying science cannot avoid a deeply uncomfortable body of experimental literature: controlled human challenge studies, conducted over more than a century, that repeatedly failed to reliably transmit illness from sick people to healthy ones.

Engler is careful here. He is not claiming viruses don’t exist. He is asking a more precise scientific question: does the conventional model — discrete pathogens, passed person-to-person in waves, causing reproducible discrete diseases — have sufficient explanatory power given what the experiments actually show?

The experiments he cites span:

His point is epistemological, not contrarian: a hypothesis that cannot reliably reproduce its central prediction under optimized experimental conditions is a hypothesis that deserves scrutiny. Science advances by testing hypotheses against evidence — not by immunizing them from challenge.

He also highlights geographic anomalies that the conventional spread model struggles to explain: Lombardy devastated while southern Italy was almost unaffected; US border cities with severe excess mortality while Canadian cities just across the border had none; the same island of Hispaniola split between the severe pandemic in Dominican Republic and the near-absence of it in Haiti — where villagers reportedly said “don’t go to hospital, that’s where people die” and where testing infrastructure was minimal.

One of the most significant and underappreciated dimensions of covid lockdown policy criticism is the complete absence from official discourse of the nocebo effect — the well-established, peer-reviewed phenomenon in which negative expectations produce real, measurable physiological harm.

The nocebo effect is the mirror image of the placebo effect. Where placebo turns positive expectations into genuine health improvements, nocebo turns fear and negative expectation into genuine illness. It has been studied for decades and is described in the mainstream medical literature.

Yet during the entire COVID response — in which populations were subjected to relentless fear messaging, told that casual social contact might kill them, and given wildly inflated estimates of individual mortality risk (surveys showed many Americans believed they had a 1-in-10 chance of dying if infected) — the nocebo effect was never discussed as even a partial explanation for outcomes.

Engler illustrates its power with two documented case studies:

The Clinical Trial Overdose: A participant in a pharmaceutical trial took a deliberate overdose of his trial medication. His blood pressure collapsed and he became semi-conscious. Hospital staff could not stabilize him. When the pharmaceutical company confirmed he was on the placebo arm of the trial, staff told him immediately. He recovered within approximately one hour, blood pressure normalizing without further intervention. The “overdose” was of inert material. The physiological collapse was entirely driven by expectation.

The Common Cold Unit Experiment: At the Salisbury Common Cold Unit, an attendant accidentally told a participant they had received nasal secretions from a sick person (rather than the sterile control). The participant developed full cold symptoms overnight. The following day, the attendant corrected the error — the participant had actually received the sterile solution. The cold symptoms resolved immediately.

Engler notes that one of the strongest predictors of COVID hospitalization was a prior history of anxiety disorders — exactly the population most susceptible to nocebo mechanisms. He argues the complete suppression of counternarratives by social media algorithms and content moderation removed the only meaningful protection against mass nocebo propagation.

For background on the nocebo effect in medical literature, see this overview from the National Library of Medicine and the Journal of Psychosomatic Research.

A concrete outcome of organized covid lockdown policy criticism was the reversal of the proposed vaccine mandate for healthcare workers in the UK NHS — a policy that would have required all doctors, nurses, and clinical staff to receive COVID vaccines as a condition of employment.

The mandate for care home workers was already in effect. The extension to all NHS healthcare workers was scheduled to take effect within weeks when it was abruptly cancelled by the government. Engler attributes this, at least in part, to sustained public and professional pressure coordinated through groups like HART, PANDA, and allied organizations.

He also points to the vaccine recommendation floor for children — kept at age 11 rather than extended downward — as a second policy outcome influenced by organized dissent.

His critique of vaccine policy extends to the influenza vaccine, where he argues the headline efficacy figures (commonly cited as 75–85% effective) are derived almost entirely from test-negative case-control studies — a methodology that measures only the propensity to test positive, not all-cause health outcomes. He notes there are essentially no randomized placebo-controlled trials of influenza vaccines demonstrating net all-cause benefit. The rationale that such trials would now be “unethical” to conduct is, to Engler, a self-sealing argument: once a vaccine is in practice, it can never be properly tested.

He describes this as a “safety Ponzi scheme” — each layer of justification resting on an unvalidated layer below, with no verifiable foundation.

The final and perhaps most systemic dimension of Engler’s covid lockdown policy criticism is his argument that COVID was not an anomaly in the behavior of public health and pharmaceutical institutions — it was a particularly visible instance of a well-established pattern.

That pattern: identify a condition likely to be chronic; incrementally redefine diagnostic thresholds; encompass an ever-larger share of the population; create a permanent treatment market.

He traces the same dynamic across:

The common mechanism is the use of narrow surrogate endpoints in drug development: a drug lowers cholesterol, therefore it is assumed beneficial; a drug lowers blood pressure, therefore assumed beneficial. All-cause outcome studies that might reveal second- or third-order harms are rarely required and increasingly rare. Engler notes that GLP-1 agonists, currently the most commercially successful drug class in history, produce significant increases in cholesterol levels — meaning many patients will be placed on statins as a downstream consequence, entering a second treatment pathway whose all-cause benefit in non-high-risk populations is itself poorly supported.

For further reading on medicalization, see Cochrane Collaboration’s vaccine and drug reviews.

Covid lockdown policy criticism, as articulated by Jonathan Engler, does not demand that COVID illness didn’t exist. It demands that:

These are not radical demands. They are the ordinary demands of evidence-based medicine and good public policy.

This post summarizes a video interview. The views expressed are those of Jonathan Engler and represent a dissenting perspective on the official COVID-19 narrative. Readers are encouraged to consult primary sources and evaluate evidence independently.

The pediatric vaccine schedule 2025 has been fundamentally rewritten. The Department of Health and Human Services officially reduced the number of routine childhood vaccine recommendations from 17 antigens down to 11 — a structural policy shift that reintroduces clinical discretion, aligns the United States more closely with peer nations like Denmark and Japan, and removes COVID-19, flu, and RSV shots from the automatic universal list. If you are a parent, a pediatrician, or anyone with a stake in childhood health policy, this change directly affects you.

In a detailed clinical interview on America Out Loud Pulse Radio, physician Clayton Baker, MD, offered one of the first on-the-record professional assessments of what the pediatric vaccine schedule 2025 update actually means, why the press reaction has been disproportionate, and what parents should be asking their doctors right now.

“HHS has announced that they have reduced the number of recommended vaccines on the pediatric vaccine schedule from 17 specific vaccines down to 11.”

— Clayton Baker, MD — America Out Loud Pulse Radio

• Pediatric Vaccine Schedule 2025: What Exactly Changed and Why It Matters
• 7 Powerful Reasons the Pediatric Vaccine Schedule 2025 Had to Change
  • 1. The United States Was a Global Outlier on Childhood Immunization
  • 2. Denmark and Japan Offer Proven, Narrower Models
  • 3. The COVID-19 Vaccine Was Never Appropriate for Universal Pediatric Mandate
  • 4. The mRNA Platform Carries Unresolved Safety Questions
  • 5. Reducing Antigenic Burden on Infants Is Clinically Rational
  • 6. The HPV Two-Dose Reduction Is Supported by Evidence
  • 7. Shared Decision-Making Is Simply Good Medicine
• Childhood Immunization Schedule Update 2025: How the Press Got It Wrong
• HHS Vaccine Schedule Changes 2025: What the AAP Split Means for Parents
• Pediatric Vaccine Schedule 2025: What Parents Should Do Right Now
• Key External Resources on the Pediatric Vaccine Schedule 2025 Update
• Conclusion: The Pediatric Vaccine Schedule 2025 Shift Is a Recalibration, Not a Repudiation

The updated pediatric vaccine schedule 2025 does not eliminate any vaccine from availability. Every shot that previously appeared on the universal list remains fully covered under the Affordable Care Act, Medicaid, CHIP, and the federal Vaccines for Children program. No parent is being told they cannot vaccinate their child. What changed is the classification of six vaccines — moving them from automatic universal recommendation to either high-risk group targeting or shared clinical decision-making between parent and pediatrician.

Here is a precise breakdown of the childhood immunization schedule update:

The most significant removals from the routine pediatric vaccine schedule 2025 list are the three mRNA-platform or mRNA-trending shots: COVID-19, flu, and RSV. Together, these represent the vaccines that required annual or recurring administration and that Baker identifies as carrying the highest unresolved evidentiary questions.

A December 2025 Presidential Memorandum directed HHS to benchmark the U.S. childhood immunization schedule update against peer developed nations. The findings were striking: the United States recommended more childhood vaccine doses than any comparable country, and in many cases more than twice the number recommended by nations with equivalent or superior pediatric health outcomes.

Two nations were prominently featured in the policy review: Denmark and Japan. Critics immediately argued that Denmark is too small and too demographically uniform to serve as a comparison point. Baker dismissed this reasoning directly, noting that Japan — with a population of 120 million people — made a deliberate decision to move the majority of its pediatric vaccine recommendations to after a child’s second birthday, and subsequently documented significant population health benefits. Japan is not a small, homogeneous country.

Baker was direct on this point: children face a statistically minimal risk from COVID-19 itself. A healthy eight-year-old, he noted, faces roughly 100,000 times less mortality risk from COVID-19 than an 80-year-old in a nursing home. Yet the COVID-19 vaccine was placed on the universal pediatric vaccine schedule 2025 predecessor list without the same evidentiary standard applied to the vaccines that remain on it. The mRNA platform used had never completed standard Phase 2 and Phase 3 clinical trials before mass rollout began.

Baker referenced two large-scale observational studies: one from South Korea covering approximately 8 million individuals and a parallel study from Italy covering around 700,000. Both found elevated cancer incidence rates among mRNA COVID vaccine recipients versus unvaccinated cohorts over a one-year follow-up period, with five of six specific cancer types matching between the two independently conducted studies.

EDITORIAL NOTE — Medical Accuracy Disclosure:

The cancer incidence findings cited above are observational and represent contested minority positions in the medical literature. They are not endorsed by the CDC, WHO, or mainstream oncology bodies. These findings have been disputed by mainstream researchers who cite confounding factors including age distribution and detection bias. Readers should consult their pediatrician and review primary peer-reviewed research before making vaccination decisions.

One of the least-discussed but most significant arguments in favor of updating the pediatric vaccine schedule 2025 is the cumulative antigenic burden placed on infants. Under the previous schedule, a child could receive six or more simultaneous injections in a single visit at six months of age. Baker cited documented reports, particularly among infant girls, of adverse outcomes following multiple simultaneous vaccinations. Regardless of which specific vaccines are involved, reducing concurrent antigenic exposure in neonates and young infants has a rational clinical basis.

The reduction of the HPV vaccine recommendation from two doses to one is not simply a cost-cutting measure. Scientific evidence has emerged indicating that a single dose provides comparable immunological protection to a two-dose series for most recipients, and adverse events have been disproportionately associated with the second dose. Baker, who has been involved in HPV vaccine injury litigation, noted that several peer nations had already adopted the single-dose protocol before the U.S. change. This update brings the U.S. into alignment with existing international evidence-based practice rather than departing from it.

The new shared decision making vaccines framework that governs the six removed vaccines does not represent a radical departure. It represents the return of informed consent as a foundational principle of clinical practice. Baker described shared decision-making as what the doctor-patient relationship in pediatrics always should have been: a conversation between a clinician and a parent, grounded in the individual child’s health profile, family history, risk factors, and values.

“Shared decision-making is basically informed consent. I don’t say to anyone: ‘Time for your flu shot, roll up your sleeve.’ I say: ‘We have the flu shot. If you’re interested, I can give it to you. If you have any questions, I can answer them.’”

— Clayton Baker, MD

The mainstream press response to the childhood immunization schedule update was rapid and largely hostile. Baker described major outlets as functioning as pharmaceutical industry mouthpieces, noting that within minutes of the announcement, headlines were warning of epidemic-level consequences without engaging in any comparative data analysis.

The two central press arguments were that the U.S. cannot be compared to Denmark because of demographic differences, and that removing vaccines from universal recommendation will inevitably increase disease burden. Baker addressed both. The Denmark comparison, he argued, collapses entirely once Japan is included in the analysis. And the claim that removing a vaccine from the universal recommendation schedule is equivalent to banning it fundamentally misrepresents what the policy change actually does.

Baker also noted that the press failed to acknowledge even a single concession: not one outlet he reviewed included the sentence “maybe we don’t need all of them.” The framing was absolute denial rather than proportionate analysis.

The American Academy of Pediatrics has declined to adopt the updated CDC schedule that reflects HHS vaccine schedule changes, publishing its own 2026 immunization guidance independently. This is an unusual and significant institutional divergence: the nation’s leading pediatric organization and the federal government are now operating on different recommendation frameworks.

For parents, this creates real-world complexity. The pediatrician in the room may be following AAP guidance. The CDC’s published schedule reflects the HHS directive. And state-level school entry requirements — which are set independently of federal recommendations — have not yet been updated in most states. Parents navigating the pediatric vaccine schedule 2025 landscape need to understand all three layers of authority.

Here is a practical action checklist for parents navigating the updated pediatric vaccine schedule 2025:

The following authoritative sources provide official and analytical context on the childhood immunization schedule update:

•  CDC Immunization Schedule Portal: CDC Recommended Immunization Schedule

•  AAP 2026 Immunization Schedule: American Academy of Pediatrics Immunization Schedule

•  WHO Global Vaccine Schedule Reference: WHO Immunization Schedules by Country

•  Brownstone Institute — Dr. Baker’s Research: Clayton Baker, MD at Brownstone.org

The pediatric vaccine schedule 2025 change is not the end of childhood vaccination. It is the beginning of a more honest conversation about which vaccines every child needs, which require individual clinical judgment, and who has the authority to make that call. The HHS decision removes COVID-19, flu, and RSV from the automatic universal list. It keeps DTP, MMR, polio, and the other long-established vaccines firmly in place. It reduces HPV from two doses to one based on emerging evidence. And it introduces a shared decision-making framework that makes federal policy consistent with basic medical ethics.

Dr. Baker’s core argument is that the pediatric vaccine schedule 2025 predecessor was not built on comparative international evidence, did not apply consistent evidentiary standards across all included vaccines, and placed an unnecessary antigenic burden on the youngest and most immunologically vulnerable patients. Whether the HHS response goes far enough is a legitimate debate. That the old schedule needed review is, increasingly, not.

The question the pediatric vaccine schedule 2025 update forces every parent and every clinician to answer is the same one that should always have been asked: not ‘What is on the list?’ but ‘What does this child need?’

About Dr. Clayton Baker, MD

Clayton Baker, MD, is a practicing physician, author, and host on America Out Loud Pulse Radio (Thursdays, 5 PM ET). He has contributed extensively to Brownstone.org on vaccine policy, public health ethics, and the COVID-19 era. His book The Medical Masquerade is available on Amazon and Barnes & Noble. Follow him on X at @CJBakerMD.

The COVID-19 pandemic policy failure may be one of the most consequential and least examined crises of our time. Professor Garrett Wallace Brown — a health economist who sat inside the UK Cabinet Office and WHO committees during the early months of 2020 — argues that those entrusted with global health security had no coherent plan, no reliable evidence base, and no accountability for the decisions that shuttered economies and cost trillions. His REPPARE project now offers a systematic, evidence-based reckoning with what went wrong — and what must change before the next outbreak.

The early months of the COVID-19 pandemic revealed a disturbing truth: those tasked with protecting global health security had “no idea what they were doing.” This assessment comes not from an outside critic, but from Professor Garrett Wallace Brown, a health economist who sat inside the UK Cabinet Office and WHO committees during the crisis.

What Brown witnessed during those critical first weeks of 2020 should concern anyone interested in pandemic preparedness and global health security. Politicians grasped for certainty amid chaos, choosing the most frightening projections under a dangerous doctrine called “no regrets.” The result? Trillions spent, economies shuttered, and a pandemic response architecture built on flawed assumptions that persists today.

• The Reckoning: Inside the COVID-19 Pandemic Policy Failure With Garrett Wallace Brown
• The REPPARE Project: Exposing Flawed Pandemic Risk Assessments
• Inflated Risk: The Evidence Doesn’t Support the Alarm
• The Economics Don’t Add Up: Pandemic Preparedness Cost Models Under Scrutiny
• The “No Regrets” Policy: How Fear Overrode Evidence
• A One-Trick Pony: The Over-Biomedicalization of Pandemic Response
• The Mpox Example: Misplaced Priorities in Action
• WHO’s Pandemic Response Reversal: Following the Crowd
• China’s Outsized Influence on Global Health Governance
• Entrenched Paradigms: Why Reform Faces an Uphill Battle
• A Path Forward: Evidence-Based Pandemic Preparedness
• Key Reform Priorities:
  • 1. Realistic Risk Assessment
  • 2. Honest Cost-Benefit Analysis
  • 3. Balanced Health System Approach
  • 4. Diverse Intervention Portfolio
  • 5. Transparent Governance
• Lessons for Future Health Emergencies
• The Stakes for Global Health Security
• About the REPPARE Project
  • Key Publications:
• Related Resources, Videos, and Links

Brown’s journey from health economics researcher to pandemic policy critic began with a simple question: How did the WHO and World Bank calculate pandemic preparedness costs? When asked to contribute data for a major preparedness cost analysis, he discovered something troubling—the inputs didn’t match the outputs, and officials couldn’t (or wouldn’t) explain their methodology.

This sparked the REPPARE project (Re-Evaluating Pandemic Preparedness and Response), a comprehensive three-year investigation examining post-COVID pandemic preparedness policy. What the research team found challenges virtually every assumption driving current global health security investments.

Current WHO pandemic risk assessments claim a major pandemic is “highly likely” within 20-40 years. The problem? This conclusion misquotes the very research it cites.

The Mariani study referenced by WHO actually estimates a COVID-scale event every 209 years, not 20-40 years. Brown’s team found this pattern repeatedly—severity models leaning heavily on the 1918 Spanish flu (which occurred before antibiotics and amid a world war), while ignoring crucial context.

Most importantly, none of these pandemic risk models account for the explosion in diagnostic capacity since 1983, when PCR testing revolutionized pathogen detection. As Brown explains: “Our diagnostic and surveillance capacities have increased exactly along the same curve as the number of new pathogens or outbreaks reported.”

When adjusted for improved detection capabilities, the trend for natural spillover events is actually downward—with COVID-19 representing an outlier, not a trend.

The financial projections driving pandemic preparedness are equally problematic. Brown’s analysis of WHO and World Bank cost estimates revealed:

“No one in their right mind would say that,” Brown notes. The moment an outbreak spreads beyond a small population, economic costs are inevitable. Yet return-on-investment calculations for pandemic preparedness assume perfect prevention—a fantasy that inflates the perceived value of current spending.

Consider the UK’s “Eat Out to Help Out” scheme, which cost billions to encourage restaurant dining after lockdowns. This wasn’t a necessary pandemic response cost—it was an expensive fix for self-inflicted economic damage. Yet such indirect costs are lumped together with legitimate pandemic expenses, artificially inflating the economic case for current preparedness strategies.

Inside UK Cabinet meetings, Brown observed a consistent pattern. Officials presented five epidemiological models weekly—none optimistic, most catastrophic. Politicians invariably chose the worst-case scenario, operating under what they called “no regrets” doctrine: better to overreact than risk blame for underreaction.

This approach explains why countries overbought PPE, overbought vaccines, and implemented extreme measures despite limited supporting evidence. Neil Ferguson’s Imperial College projections consistently showed the most frightening outcomes and received disproportionate weight, despite questions from the Office of National Statistics about inflated estimates.

The evidence was there for a different approach. Diamond Princess cruise ship data clearly showed age-stratified risk. The French aircraft carrier Charles de Gaulle demonstrated minimal impact on young, healthy military populations. Yet this nuanced evidence was “largely ignored” in favor of population-wide panic measures.

Perhaps most concerning is the governance structure emerging from COVID-19. Every major institution created or empowered—the Pandemic Fund, the 100-Day Vaccine Mission, the German BioHub, new countermeasure distribution systems—follows the same narrow playbook:

“It’s a one-trick pony,” Brown warns. This biomedicalized approach ignores the real killers claiming millions annually: tuberculosis (1.3 million deaths per year), malaria (47,000 children dead annually in DRC alone), and basic health system weaknesses.

The WHO’s priority pathogen list—including the mysterious “Disease X”—accounts for just 17,000 total historical deaths across all listed diseases combined. Yet these rare exotic threats receive disproportionate attention and resources compared to endemic diseases with massive proven impacts.

The recent Mpox response in Democratic Republic of Congo illustrates this misallocation. With 55 deaths from Mpox (spread primarily through direct contact, not airborne transmission), the international response allocated resources equivalent to $1.2 million per life saved.

Meanwhile, 47,000 children die from malaria in DRC annually, and basic health clinics lack reliable electricity. As Brown pointedly asks: “You can’t keep the lights on in your clinics and you’re going to spend 1.2 million per life saved?”

Brown’s findings on WHO behavior during COVID-19 reveal an organization that followed rather than led. The WHO’s 2019 “Managing Epidemics” handbook explicitly advised against:

Yet by 2022, the second edition normalized all these interventions. What changed? Not the evidence—the WHO simply adapted its guidance to match what countries were already doing, likely to preserve institutional authority after being ignored during the crisis.

Brown identifies a troubling dynamic in UN health agencies: dependence on China’s development statistics to demonstrate global progress. China’s dramatic poverty reduction has masked stagnation elsewhere, creating perverse incentives.

“If you want to see progress towards your UN goals, you get China to do it,” Brown observes. This dependency may explain the WHO’s deference to Chinese authorities during early pandemic response, when critical information sharing lagged.

Despite clear evidence of pandemic policy failures, changing course remains difficult. Brown identifies a “bad cocktail” of factors perpetuating the status quo:

Having participated in G7 and G20 meetings five times each and sat on WHO subcommittees, Brown understands how these forces operate. “Politicians are told things, they don’t even know if it’s right or wrong. They’re just told.”

The REPPARE project doesn’t argue against pandemic preparedness—it argues for honest, evidence-based preparedness that doesn’t sacrifice known solutions for hypothetical threats.

Brown’s Swedish-style recommendations during COVID-19—protecting the vulnerable, avoiding long lockdowns, keeping schools open—were derided as reckless at the time but have since been largely vindicated. His warnings against putting “all our eggs in one basket” with vaccination-only strategies proved prescient as variants emerged and vaccine effectiveness against transmission disappointed.

The core lesson isn’t that preparation is unnecessary—it’s that panic-driven preparation creates its own catastrophe. As Brown told his wife after that first Cabinet meeting: “These people have no idea what they’re doing.”

Five years later, with pandemic preparedness architecture firmly entrenched, the question remains: Will evidence matter more than fear next time?

The decisions made now about pandemic preparedness will shape global health for decades. Every dollar directed toward hypothetical exotic pathogens is a dollar not spent on tuberculosis, malaria, maternal health, or strengthening fragile health systems in low-resource settings.

Brown’s research suggests we’re building the wrong architecture—securitized, biomedicalized, and unmoored from evidence. The paradigms are strong, the interests entrenched, but the possibility of course correction exists if political will can be mustered.

“Maybe it’s hope before reality,” Brown acknowledges. But with projects like REPPARE forcing honesty about pandemic evidence, costs, and priorities, there’s a chance to “repair” what went wrong before the next panic takes hold.

The REPPARE project (Re-Evaluating Pandemic Preparedness and Response) is a three-year research initiative examining post-COVID pandemic policy and governance. Led by Professor Garrett Wallace Brown at Leeds University, the project has published 15+ academic articles in major journals including The Lancet, with comprehensive reports on zoonotic risk, cost and financing, and governance architecture.

For researchers, policymakers, and public health professionals seeking evidence-based pandemic preparedness strategies, the REPPARE findings offer crucial insights into building more effective, proportionate, and accountable health security systems for future global health emergencies.

https://www.americaoutloud.news/garrett-wallace-brown-on-pandemic-policy-failure/

https://essl.leeds.ac.uk/politics/staff/64/professor-garrett-wallace-brown

https://essl.leeds.ac.uk/directories0/dir-record/research-projects/1260/re-evaluating-the-pandemic-preparedness-and-response-agenda-reppare

Pandemic preparedness funding has grown into a $30–40 billion annual industry—ten times the entire WHO operating budget. Dr. David Bell, a former WHO physician now leading the REPPARE Project at the University of Leeds, has spent years reviewing the data behind these investments. His conclusion is troubling: the money is not flowing toward the world’s deadliest diseases. Instead, it is being channeled through public-private partnerships that serve pharmaceutical shareholders, institutional bureaucracies, and fear-driven narratives—not the populations most in need.

• Pandemic Preparedness Funding Exposed: Is the Industry Built on Fear?
  • The Rise of Pandemic Preparedness Funding: Follow the Money
    • WHO Pandemic Agreement: A New Financial Architecture
    • Gates Foundation and the Global Health Funding Machine
  • REPPARE Project: What the Evidence Actually Shows
    • WHO’s Priority Disease List Under the Microscope
    • The COVID Data Inflation Scandal
    • Their methodology assumes:
  • Why Pandemic Preparedness Funding Doesn’t Fix Real Health Crises
    • Pandemic Preparedness as Revenue Stream
    • The Pandemic Fund and Global Health Security
  • Academic Capture: When Health Science Becomes Marketing
  • Climate Change: The Perfect Partner Narrative
  • The Path Forward: Restoring Integrity to Global Health Funding
    • Why REPPARE Matters
    • Real Threats Left Behind While Pandemic Budgets Balloon
  • Conclusion: Admitting the Problem Before Finding the Answer
  • FAQ’s
    • What is pandemic preparedness funding?
    • Who controls WHO’s pandemic budget?
    • What is the REPPARE Project?
  • Key Takeaways
  • About REPPARE and Dr. David Bell

The pandemic preparedness narrative has reached fever pitch. The World Bank and WHO speak of “existential threats” requiring $30-40 billion annually—ten times WHO’s current total budget. In May 2025, the WHO Pandemic Agreement was formally adopted after three years of negotiation, cementing this new financial architecture.

But here’s what most people don’t know: WHO’s funding structure has fundamentally changed. Bell explains that 80% of WHO funding is now earmarked by specific donors for specific projects—a radical departure from the pooled country contributions that once gave the organization independence.

The Gates Foundation has become WHO’s largest single funder, surpassing even the United States following America’s announced withdrawal in 2025. Between 2000 and 2024, the Foundation donated $5.5 billion to WHO—with over 50% directed toward vaccines and polio programs.

As Bell notes with measured concern: “A company can only participate significantly in a public-private partnership if they think they’ll make money out of it.” This isn’t conspiracy—it’s basic economics. When pharmaceutical representatives sit on boards deciding how to spend public money, they fulfill their fiduciary duty to shareholders, not global health needs.

Bell’s team scrutinized WHO’s R&D Blueprint—the list of diseases supposedly threatening humanity. The findings are remarkable:

“There is nothing on that list that would logically cause you much concern,” Bell states. “Infectious disease deaths have been declining for a century.”

Perhaps REPPARE’s most explosive finding concerns how COVID deaths are being counted for posterity. The Institute for Health Metrics and Evaluation (IHME)—funded by the Gates Foundation and considered the “gold standard” for disease burden data—has created models that systematically inflate COVID deaths while minimizing collateral damage from lockdowns and vaccines.

Using these assumptions, IHME converts the 15.9 million excess deaths during 2020-2021 into predominantly COVID deaths, particularly in African nations with low vaccination rates. As Bell warns: “We’re building a false history. Someday people will believe these numbers are real.”

Bell doesn’t speak in conspiratorial whispers. He speaks with the resignation of someone who understands bureaucratic incentives:

“If you’re running a research lab, your main concern is making sure your staff don’t get sacked because you run out of money. If there’s $200 million earmarked for Zika vaccine research, you’ll work on Zika—not because we need it, but because the funding is there.”

The same logic applies throughout the system:

The World Bank’s Pandemic Fund, established in 2022, has awarded $885 million in grants, catalyzing over $6 billion in total resources across 75 countries. While proponents celebrate this investment in global health security, critics like Bell ask: investment in what, exactly?

When malaria kills far more people annually than any disease on WHO’s priority list, when tuberculosis and HIV remain major killers, when basic sanitation would prevent millions of deaths—why are we directing resources toward theoretical pandemics?

Bell is candid about the systemic problem: “Science has become marketing. Almost all nutrition research is funded by food companies. Almost all health research is funded by pharmaceutical ones. You get the results the sponsors want.”

The Neil Ferguson example is instructive. His Imperial College models predicted 500,000 UK deaths and 3 million US deaths from COVID—projections that justified lockdowns and eventually vaccine mandates. At the same time, Ferguson co-authored a Lancet paper showing almost no one under 65 died from COVID.

“Did he publish contradictory data?” one might ask. Yes. “Did it matter?” Apparently not when funding comes from interested parties.

The WHO now officially claims climate change is “driving” malaria increases, despite evidence pointing to drug resistance, insecticide resistance, poverty, and civil war. Meanwhile, malaria is being successfully eliminated in temperate countries—exactly where climate warming should theoretically have the greatest impact.

As Bell observes: “If you’re doing vaccines, you will work on Zika not because we need a Zika vaccine but because there is $200 million sitting there waiting.”

The same dynamic applies to climate-pandemic linkages. Once you establish climate change as an amplifier of infectious disease risk, you unlock additional funding streams. The science becomes secondary to the narrative that unlocks resources.

Bell remains guardedly hopeful, citing universities like Leeds that still “permit integrity” and organizations like Brownstone Institute that fund independent research without demanding predetermined outcomes.

The REPPARE Project’s methodology is simple but powerful: examine the evidence that institutions like WHO, World Bank, and G20 use to justify their claims. Don’t accept consensus. Don’t defer to authority. Check the citations.

What they’ve found repeatedly: institutional claims contradict their own cited evidence.

While billions flow toward pandemic preparedness, the actual killers receive inadequate attention:

“We still have major problems in real health,” Bell emphasizes, “and billions are wasted chasing phantoms.”

Dr. David Bell’s message is both sobering and essential: we have to start admitting the problem before we can find the answer.

The pandemic industry has created a self-reinforcing cycle where:

Breaking this cycle requires what Bell and REPPARE are doing: meticulous evidence review, intellectual honesty, and the courage to challenge powerful institutions.

As Bell concludes: “The incentives are wrong. The system rewards fear.” Until we realign incentives toward actual health outcomes rather than theoretical catastrophes, global health will remain captured by profit and politics.

The question isn’t whether another pandemic will come. The question is whether we’ll use public resources to address real health needs—or continue feeding an industry built on manufactured fear.

Pandemic preparedness funding refers to the financial resources allocated by governments, international institutions, and private donors to prevent, detect, and respond to infectious disease outbreaks before they become global crises. In recent years, this funding has grown dramatically — the World Bank and WHO now call for $30–40 billion annually to be directed toward pandemic preparedness infrastructure, surveillance systems, and vaccine development programs. Critics, including researchers at the REPPARE Project, argue that pandemic preparedness funding is increasingly misallocated toward theoretical disease threats and pharmaceutical-aligned priorities, while proven killers like malaria, tuberculosis, and unsafe water — which claim millions of lives every year — remain chronically underfunded.

WHO’s pandemic budget is no longer controlled primarily by member states. Today, approximately 80% of WHO’s funding is earmarked by specific donors for specific projects — meaning donors, not elected governments, effectively set the agenda. The Gates Foundation has become WHO’s single largest funder, having contributed $5.5 billion between 2000 and 2024, with over half directed toward vaccines and polio programs. Following the United States’ announced withdrawal in 2025, this concentration of influence has grown even more pronounced. The May 2025 WHO Pandemic Agreement further cemented this new financial architecture, raising serious questions about whose interests global pandemic preparedness funding ultimately serves.

The REPPARE Project — short for Rethinking Evidence, Policy, and Pandemic Response Evaluation — is an independent research initiative based at the University of Leeds. Led by Dr. David Bell, a physician and former WHO specialist in tropical medicine, and Professor Garrett Brown, Chair of Global Health Policy, REPPARE conducts forensic reviews of the evidence used by institutions like the WHO, World Bank, and G20 to justify pandemic preparedness funding decisions. Their findings have repeatedly shown that institutional claims often contradict the very sources they cite — including inflated COVID death counts, overstated disease risks, and systematic undercounting of lockdown-related harms. REPPARE is supported by the Brownstone Institute and operates with full editorial independence.

✓ Pandemic preparedness funding has grown to $30-40 billion annually, 10x WHO’s total budget ✓ Gates Foundation is now WHO’s largest single funder, directing 50%+ toward vaccines ✓ WHO’s priority disease list contains no pathogen that has killed more than a few thousand people ✓ Global burden of disease data is systematically inflating COVID deaths while minimizing lockdown harms ✓ Public-private partnerships direct taxpayer money toward pharmaceutical profits ✓ The REPPARE Project provides independent evidence review of pandemic industry claims ✓ Real health threats (malaria, TB, sanitation) remain underfunded while theoretical pandemics absorb resources

The REPPARE Project (Rethinking Evidence, Policy, and Pandemic Response Evaluation) operates from the University of Leeds, providing independent analysis of pandemic preparedness policies and claims. Dr. David Bell, a physician specializing in tropical medicine with extensive WHO experience, leads the evidence review alongside Professor Garrett Brown, Chair of Global Health Policy at Leeds. Their work is supported by Brownstone Institute and conducted with complete independence—a rarity in today’s funding environment where research outcomes are often predetermined by donor interests.

In a sweeping interview, Dr. Robert Malone provides a critical update on the seismic shifts occurring within the Trump administration’s approach to public health—shifts that represent nothing less than a philosophical war over the future of medicine itself. From RFK Jr.’s historic rejection of globalist health declarations to explosive revelations about vaccine policy and autism research, the battle lines are being drawn between individual liberty and collective control.

Follow Dr. Robert Malone

• The UN Rejection: A Historic Stand for National Sovereignty
• The Autism Press Conference: Twenty Years in the Making
• The Tylenol-Autism Connection: Science or Politics?
• The Backlash: “Committing Violence Against the Truth”
• The Philosophical Battle: Utilitarian Bioethics vs. Patient-Centered Medicine
• The Greatest Happiness Principle—And Its Dangers
• The CDC Crisis: Leadership Vacuum and Scientific Decay
• The MMWR Problem
• Pediatricians Firing Patients: An Ethical Crisis
• Operation Warp Speed: Achievement vs. Product Safety
• The Malone “Hostage Video”: Vindication Through Data
• The Measles Case Study: When Bias Blinds Medicine
• The Bigger Battle: Liberty vs. Collectivism
• The Pace of Change: “Wicked Fast”
• Looking Forward: Three More Years and Beyond
• Conclusion: The Soul of Medicine at Stake

Secretary of Health and Human Services Robert F. Kennedy Jr. made headlines by delivering an unequivocal rejection of the United Nations’ new health declaration at the UN General Council—a document actively promoted by the World Health Organization (WHO). Dr. Malone characterizes this as “a blanket unequivocal rejection to globalism” the likes of which have rarely, if ever, been heard from a U.S. government representative.

The health declaration, according to critics, contained what Malone describes as “the usual subtext of Trojan horse that would compromise national sovereignty” by allowing increased surveillance and international oversight of domestic health policies. Kennedy’s five-minute speech, which corporate media largely ignored, represents a fundamental shift in how the United States engages with international health organizations.

When have you heard that from a representative of the US government?” Malone asks, noting the historic nature of Kennedy’s direct challenge to the UN and WHO’s authority.

Perhaps even more explosive was President Trump’s recent press conference addressing autism, vaccine schedules, and the contentious Tylenol-autism connection. According to Dr. Malone, this wasn’t a spontaneous event—Trump opened the conference by stating he had been “waiting for this for 20 years.

The timeline is significant: approximately twenty years ago, Trump and RFK Jr. had discussions about these very issues, coinciding with Baron Trump’s birth. Dr. Malone suggests that Trump’s personal experience with Baron—who reportedly exhibits some social characteristics associated with autism spectrum disorder (ASD)—has fueled the president’s long-standing commitment to understanding the autism epidemic.

One of the most controversial elements of the press conference was the president’s endorsement of data linking prenatal Tylenol (acetaminophen) use to autism and ADHD. Dr. Malone, having reviewed the scientific literature, confirms there is indeed “significant data supporting the association.”

The mechanism of action involves glutathione depletion—the same biochemical pathway affected by folate metabolism, which explains why leucovorin (a folate-like molecule) has shown remarkable clinical improvement in some ASD patients. Malone explains: “The folate receptor in some of these cases with ASD is either compromised through an autoimmune process or some other process, and you can bypass that receptor.”

However, critics point to contradictory studies, particularly a notorious Dutch study that Malone systematically dismantles. The Dutch researchers, he notes, focused only on prescription acetaminophen use while failing to account for over-the-counter usage—meaning both control and treatment groups were actually taking Tylenol, rendering the comparison meaningless.

The response to Trump’s autism statements was swift and revealing. Former President Barack Obama released a video claiming that Trump’s press conference represented “committing violence against the truth”—a statement Malone calls “a propaganda statement that is profoundly twisted.”

Even more disturbing was the social media phenomenon of pregnant women posting videos of themselves consuming excessive amounts of Tylenol in protest, with at least one woman reportedly hospitalized with fulminant liver failure. Malone notes darkly that “apparently nobody gave them the memo that Tylenol can actually kill you through fulminant liver failure and it’s a nasty way to die.”

At the heart of these controversies lies a fundamental philosophical divide that Dr. Malone identifies as the true battleground of modern medicine. He explains that the academic world of bioethics has undergone a revolution since he took his bioethics training, with the emergence of what’s called “utilitarian bioethics.”

Utilitarian bioethics operates on the principle of promoting “the greatest happiness for the greatest number.” While this sounds benign, Malone warns of its inherent dangers: “The power all flows to whoever defines happiness.”

This represents a fundamental departure from traditional medical ethics, which historically focused on the individual patient. As Malone frames it: “Public health is fundamentally based on utilitarian logic and focused on advancing the interests of the collective. Medical practice historically is focused on the patient as an individual, not a patient as a member of a broader collective society.”

The implications are profound. Under utilitarian bioethics, individual patient rights can be subordinated to collective interests—as we saw during COVID-19 lockdowns and vaccine mandates, where specific parameters were optimized while “other impacts were disregarded in the overall analysis.

Malone points to an alarming example from an American medical school bioethics group that seriously proposed engineering all humans to be allergic to meat (via the alpha-gal pathway from tick bites) because “eating meat is bad for the environment.” He initially thought it was satire—it wasn’t.

Dr. Malone reveals a stunning fact that few Americans know: the CDC has not had an onsite director for decades. Former Director Michelle Walensky, for instance, stayed at her home in New England throughout her tenure.

“The place has been allowed to run itself,” Malone explains, with the consequence being that “we have decades of slide in terms of scientific rigor and quality.”

He identifies three key bureaucrats who recently resigned from the CDC—individuals who were functionally running the agency. The result has been an institution captured by what Malone describes as “B and C level minds” hired under the government’s “lowest cost technically acceptable” contracting philosophy.

The CDC’s Morbidity and Mortality Weekly Report (MMWR), historically held in high regard, is actually non-peer-reviewed. “If you’re a CDC employee and you come up with some report about whatever it is you’ve been doing, you can slip it into the MMWR. It gets no peer review,” Malone reveals.

This lack of rigorous oversight extends to diagnostic testing. When Malone challenged CDC officials about the sensitivity, specificity, and positive predictive value of COVID-19 PCR tests—fundamental epidemiological metrics—the response was dismissive: “those are academic questions.

One particularly troubling practice Dr. Malone highlights is the growing trend of pediatricians firing families who refuse certain medical interventions. According to a 2020 survey, 34% of pediatricians indicated they would terminate the doctor-patient relationship if parents refused not just vaccines, but even vitamin K shots for newborns.

“That is not ethically acceptable,” Malone states firmly. “We’re in theory as a profession bound to treat our patients to the best of our ability. This business of ‘well, if you won’t accept my paternalistic mandate, then you’re out’—that’s just bizarre behavior.”

This practice exemplifies the shift from patient-centered care to a collective-focused, mandate-driven model that prioritizes compliance over the physician’s duty to serve individual patients.

Dr. Malone offers a nuanced perspective on Operation Warp Speed that’s often missing from both sides of the debate. He credits it as “a remarkable achievement in cutting across silos and enabling a whole of government response,” particularly in getting the Department of Defense and HHS to cooperate—historically difficult due to turf battles over biodefense authority.

However, he clearly separates process from product: “That’s separate from the issue of whether the work product was safe and effective as advertised.”

Regarding Pfizer CEO Albert Bourla’s suggestion that Trump deserves a Nobel Prize for Operation Warp Speed, Malone notes the cynical nature of the statement, pointing out that the Nobel Prize in Medicine was already awarded to Karikó and Weissman for mRNA technology and “doesn’t give isn’t given for the same topic twice.

Dr. Malone addresses attacks on his 2021 video warning parents about COVID vaccine risks for children—attacks that resurfaced during Kennedy’s confirmation hearings. In that three-minute segment, which went globally viral and prompted official responses from the Israeli and Spanish governments, Malone warned that:

At the time, he was vilified for these statements. But recent ACIP presentations have documented IgG4 class switching and “a variety of other immunologic suppression pathways” that validate his warnings.

“The things that went down at ACIP recently were pretty big time,” Malone notes, referring to unprecedented dissent among committee members—”exactly what you would expect if you had a group of scientists actually trying to make decisions about data.”

Malone recounts a tragic case from West Texas that illustrates how media narratives can compromise medical judgment. Two young girls from an unvaccinated Mennonite community died after being treated for presumed measles pneumonia. However, they actually had secondary bacterial or mycoplasma infections—completely treatable conditions.

“There were clinical signs and symptoms as well as laboratory diagnostic signs that clearly demonstrated that those patients did not have measles pneumonia,” Malone explains. Both cases are now being pursued as medical malpractice because physicians, pre-wired by media coverage to assume measles, failed to properly diagnose and treat bacterial pneumonia.

This mirrors what happened with COVID-19: “If you presented with upper respiratory symptoms during COVID, you were by default considered to have COVID,” regardless of whether it might be influenza, RSV, or other respiratory viruses.

Dr. Malone frames the entire medical freedom debate within a larger philosophical and political context—what he calls “the historic battle” between two competing visions of society.

On one side: the liberty-focused framework embodied in the U.S. Constitution and Bill of Rights, emphasizing individual rights and personal sovereignty. Liberty, Malone notes, is distinct from mere freedom—it’s “the intersection of freedom and responsibility.”

On the other: the collectivist model associated with Marxist thought and social justice movements, prioritizing group outcomes over individual autonomy.

“This fundamental dialectic exists within society of whether we want to be prioritizing the rights of the collective over the rights of the individual,” Malone states. “I’m ready to have that fight.”

He connects this to the broader cultural moment, noting that Secretary Kennedy’s UN speech and the Trump administration’s rapid policy changes represent an unprecedented pushback against globalism and collectivist health policies.

Perhaps most remarkable is the sheer velocity of transformation occurring within HHS. Malone describes the news cycle as “wicked” (using the Boston regional intensifier), meaning events are unfolding so rapidly that “it is very difficult to keep up.”

From Kennedy’s UN speech to Trump’s autism press conference to ACIP meeting upheavals to CDC director changes—the administration is creating what one of Malone’s colleagues describes as a “rope-a-dope” strategy. Like Muhammad Ali’s famous boxing technique, the Trump administration positions issues in ways that cause corporate media and medical establishment to reflexively defend untenable positions, further delegitimizing themselves.

“He can take whatever position he wants,” Malone observes. “They say ‘not A’ reflexively, like oppositional defiant disorder.”

With three and a half years remaining in Trump’s term (and the possibility of JD Vance continuing these policies), Dr. Malone is optimistic about lasting change. He notes that by the time a potential Vance administration ends, key globalist figures like Bill Gates and George Soros will likely be gone, creating space for a fundamentally different public health paradigm.

However, he also warns of emerging threats like Palantir, central bank digital currencies, and other technological tools that could infringe on personal liberty in new ways.

The comparison to historical revolutions is apt: as Malone notes, both sides are living out 18th-century conflicts—the American Revolution’s emphasis on individual liberty versus the French Revolution’s collective focus. Trump, in this framework, serves as a restorative figure challenging decades of leftist institutional capture.

Dr. Robert Malone’s wide-ranging analysis reveals that current health policy battles are not merely about specific drugs or disease management strategies. At stake is the fundamental philosophical orientation of medicine itself: Will we return to a patient-centered model that honors individual autonomy and informed consent? Or will we continue down the path of utilitarian bioethics that subordinates individual welfare to collective metrics?

The Trump administration’s approach—from Kennedy’s rejection of WHO declarations to challenges of vaccine schedules to investigations of autism causes—represents a comprehensive repudiation of the utilitarian model that has dominated public health for decades.

As Malone concludes, this is nothing less than “a political, scientific, and philosophical war being waged for the future of public health.” The outcome will determine whether medicine returns to its traditional ethical foundations or continues its drift toward collectivist control.

For those paying attention, these are indeed extraordinary times.

Find Dr. Randall Bock’s articles at Brownstone:

Follow Dr. Randall Bock on Substack:

Get Dr. Randall Bock’s Book “Overturning Zika: The Pandemic That Never Was:

Attorney Aaron Siri approaches vaccines not as a medical professional, but through the lens of law and evidence. His investigation into vaccine licensing and clinical trials reveals a stark disconnect between public perception and regulatory reality. As he puts it simply: “They’re just products. Judge them as products.”

• A Lawyer’s Perspective on the Sacred and the Scientific
• The Historical Context: Before the Vaccine Explosion
• The COVID Vaccine Paradox: Our “Best” Trials Were Still Inadequate
• The Placebo Problem: No True Controls in Childhood Vaccine Trials
• Safety Monitoring: Days and Weeks, Not Months or Years
• The Legal Shield: Unique Immunity from Liability
• The Religion of Vaccines: Belief Versus Evidence
• The Health Crisis: Correlation and Causation
• Individual Rights and Informed Consent
• The Path Forward: Products, Not Sacred Objects
• Conclusion: Evidence Over Emotion

Siri begins with a historical perspective that challenges modern assumptions. “In the early eighties, we had three routine vaccines—MMR, OPV, DTP. That was it. No apocalypse.” The vaccination uptake rates were modest—high 50s to low 60s percent—yet society functioned without the dire consequences often predicted today.

Children routinely contracted and recovered from measles, mumps, and chickenpox through natural exposure. While these illnesses were certainly inconvenient and sometimes dangerous, they didn’t collapse civilization. More intriguingly, “study after study shows those who had measles, mumps, rubella, and chickenpox have lower rates of cancer and far lower rates of heart disease.”

This raises questions about the long-term trade-offs when we eliminate these natural infections entirely.

The COVID-19 vaccines faced criticism for rushed development and abbreviated trials. Yet Siri reveals a stunning comparison: “The COVID vaccine trials, as short as they were, were more robust than almost any childhood vaccine trial.”

COVID vaccine trials included:

This stands in sharp contrast to the routine childhood vaccines that parents accept without question.

Siri’s most damning finding centers on basic scientific methodology: “Not a single routine injected childhood vaccine was licensed on a placebo-controlled trial with something inert. Not one.”

Instead of using true placebos—inert substances that allow researchers to distinguish vaccine effects from background health issues—vaccine trials typically use:

This fundamental flaw undermines the ability to accurately assess vaccine safety profiles.

The duration of safety monitoring in childhood vaccine trials is shockingly brief:

Hepatitis B vaccine: 147 children, 5 days of safety monitoring MMR vaccine: 800 children, 42 days of safety review Most routine vaccines: “Days. Weeks. Laughable,” as Siri describes it

Compare this to pharmaceutical drugs, which undergo multi-year placebo-controlled trials specifically because drug companies want to identify safety issues before facing potential lawsuits.

Vaccines occupy a unique position in American law. Unlike every other product—from cars to pharmaceuticals to household items—vaccine manufacturers enjoy complete immunity from design defect lawsuits under the 1986 National Childhood Vaccine Injury Act.

This removes the normal market incentive to develop safer products. As Siri notes, drug companies have strong financial motivation to conduct thorough safety testing because they face liability for injuries. Vaccine manufacturers operate under different rules entirely.

Siri identifies a cultural phenomenon where vaccines have transcended scientific scrutiny to become objects of faith. People commonly say “I believe in vaccines” rather than “I’ve examined the evidence for vaccines”—a telling linguistic shift that suggests emotional rather than rational engagement with the topic.

“Most of what people know about vaccines is based on belief,” Siri observes. “That’s why when you challenge them on it, they often react emotionally because they’re not drawing from their intellect, their knowledge. They’re drawing from their emotions because they have no place else to draw from.”

The timeline correlation is striking. As childhood vaccine injections increased from 3 by age one (early 1980s) to 29 by age one (today), chronic health conditions in children exploded from under 10% to over 40%—with some estimates exceeding 70%.

Many of these conditions involve immune system dysregulation:

While correlation doesn’t prove causation, it warrants serious investigation rather than dismissal.

Siri’s legal work focuses on protecting individual choice and genuine informed consent. His position is straightforward: “If you want to get a vaccine, this is America. That’s freedom. You should be free to get as many as you want. But if you do not want to get a vaccine, you’ve been informed, you’ve looked at it, and you decide, I don’t want to consent, that’s informed consent.”

The issue isn’t whether vaccines are inherently good or bad, but whether people can make truly informed decisions based on complete information rather than marketing claims.

Siri’s core message is simple: treat vaccines like any other medical product. This means:

“I’m not for or against vaccines,” Siri explains. “I don’t think they’re good or they’re bad. They’re a product. Judge them as products.”

The conversation around vaccines has become so emotionally charged that basic questions about clinical trial methodology are often dismissed as heretical. Siri’s legal investigation suggests we need to return to fundamental scientific principles: proper controls, adequate safety monitoring, and honest assessment of risks and benefits.

Whether vaccines provide net benefits in specific circumstances is a question that deserves rigorous, unbiased investigation rather than faith-based acceptance. The goal isn’t to eliminate all vaccines, but to ensure they meet the same evidentiary standards we demand of other medical interventions.

As Siri concludes: vaccines are products, not objects of worship. It’s time we started treating them as such.

Political scandal erupts as Senator Blumenthal attacks vaccine scientist Dr. Robert Malone over CDC shooting. Learn about stolen valor claims, ACIP controversy, and free speech debates in this explosive political clash.

• The Stolen Valor Senator Strikes Again
• A Pattern of Deception: Blumenthal’s Vietnam Lies
• The Real Story Behind Blumenthal’s Military Service:
• The Modern Drive-By: Attacking Dr. Malone
• The Manufactured Controversy
• Key Facts About the Attack:
• Free Speech Under Fire: The First Amendment Implications
• The Bigger Picture: Silencing Vaccine Skeptics
• Why This Matters:
• The ACIP Connection: Kennedy’s Revolutionary Appointments
• Defending the Status Quo
• The Dangerous Precedent: Criminalizing Satire
• What This Means for Americans
• The Pattern Continues: From Vietnam to Virginia
• Moving Forward: The Need for Accountability

In the halls of Washington D.C., where political scandals brew daily, Senator Richard Blumenthal has once again found himself at the center of controversy. This time, his target isn’t a political opponent but Dr. Robert W. Malone, a respected vaccine scientist and ACIP committee member appointed by HHS Secretary Robert F. Kennedy Jr.

Blumenthal’s credibility problem isn’t new. Back in 2008, he boldly told veterans, “We have learned something important since the days that I served in Vietnam.” The truth tells a different story entirely.

In 2003, Blumenthal doubled down on his deception, telling Iraq and Afghanistan veterans, “When we returned, we saw nothing like this.” These statements represent classic stolen valor – falsely claiming military honors and experiences never earned.

Now, from his secure Washington perch, Blumenthal has targeted Dr. Robert W. Malone with what can only be described as a political drive-by shooting. In August 2025, following a tragic incident at the CDC where a disturbed gunman killed a police officer, Blumenthal immediately weaponized the tragedy for political gain.

Blumenthal’s attack centered on a meme Dr. Malone had posted hours before the shooting – a piece of satirical content completely unrelated to the tragic events. As Malone explained, “Blumenthal basically accused me of thought pre-crime because I had posted that particular meme at ten-thirty in the morning when the shooting occurred at five PM.”

This controversy goes far beyond personal politics – it strikes at the heart of constitutional rights. Dr. Malone’s response was clear: “Apparently, based on Senator Blumenthal’s attacks on me, I would say he’s also an opponent of the First Amendment. Because this is just free speech and moreover, it’s humor — the last bastion in a tyranny of freedom of speech for free people.”

Blumenthal’s attack isn’t isolated but part of a systematic pattern targeting those who question vaccine research and public health orthodoxy. Dr. Robert Malone, who had worked on early research into mRNA technology but is now critical of mRNA vaccines, has suggested that COVID vaccines may cause cancer. His appointment to the ACIP committee represents a significant shift toward transparency in vaccine policy.

The new members will join the Advisory Committee on Immunization Practices, or ACIP, which advises the Centers for Disease Control and Prevention. Robert F. Kennedy Jr.’s appointment of vaccine-critical scientists like Malone to the ACIP committee has shaken the medical establishment to its core.

Blumenthal’s aggressive targeting of Malone appears designed to:

Perhaps most concerning is Blumenthal’s apparent inability – or unwillingness – to distinguish between satirical content and genuine threats. His Harvard magna cum laude education seems worthless when applied to real-world situations requiring basic judgment and constitutional understanding.

When elected officials begin treating humor and political satire as potential criminal acts, we’ve crossed a dangerous line. The incident raises serious questions about:

The connection between Blumenthal’s stolen valor past and his current attacks on Dr. Malone reveals a consistent pattern of deception and opportunism. Whether fabricating military service or manufacturing controversies, the Senator demonstrates a troubling willingness to distort truth for political gain.

As this political scandal unfolds, Americans must ask themselves: Can we trust elected officials who’ve built careers on lies to suddenly champion truth? The Blumenthal-Malone controversy serves as a stark reminder of why transparency, honest debate, and constitutional protections remain essential in our democracy.

The stakes couldn’t be higher: When senators attack scientists for posting memes while claiming stolen military valor, our political system has reached a crisis point that demands immediate attention from voters and fellow lawmakers alike.

Related Keywords: political corruption, government accountability, military service fraud, vaccine policy, scientific debate, constitutional rights, political weaponization, medical freedom

Attorney Lucia Sinatra, spearhead for No College Mandates, joins us to discuss the origins of the organization and the legal battle against Covid 19 vaccine mandates. She shares her personal story as a mom of college students and her shock at the oppressive policies implemented by universities like Rutgers and Harvard, which led to students being forced to dis-enroll and have their lives ruined. Sinatra explains the unscientific and dangerous nature of these mandates and the group of lawyers at Freedom Counsel who are fighting for medical freedom and informed consent for students.

Public health should be about saving lives, right? But what happens when billions of dollars meant to protect us get diverted into shadowy projects, political kickbacks, and risky experiments? Investigative journalist Paul Thacker joined Randy Bock on a recent podcast to unravel how funds intended for pandemic preparedness ended up fueling gain-of-function research, media collusion, and questionable payoffs. Let’s dive into the murky world where science meets politics—and why your health might not be the priority.

• Introduction: The Tangled Web of Public Health and Politics
• The Global Virome Project: A Virus Collection Gone Rogue
  • Origins and Illicit Funding
  • EcoHealth Alliance: The Middleman in High-Stakes Research
• Fauci’s Controversial Legacy: From Hero to Villain?
  • Gain-of-Function Research and the COVID Cover-Up
  • “Pathological Liar” or Scapegoat?
• Vaccine Controversies: Hidden Data and Media Silence
  • Pfizer’s Buried Adverse Events
  • The Media’s Complicity
• Public Health’s Misplaced Priorities
  • Chronic Diseases vs. Pandemic Panic
• Media Collusion and the CIA’s Hidden Hand
  • Reporters with Secret Agendas
  • Propaganda Tactics: Creating Confusion
• Political Payoffs and the NGO Shell Game
  • The Clinton Foundation Parallel
  • Hunter Biden and the “Wormhole Money”
• COVID Origins: Lab Leak or Natural Spillover?
  • The Case for a Wuhan Lab Accident
  • Intelligence Community Conflicts
• Lockdowns: A Failed Experiment
  • Cultural and Economic Fallout
• Accountability: Will Anyone Face Consequences?
  • State AGs Demand Answers
  • Reforming Public Health
• Conclusion: A System in Crisis
• FAQs

Imagine a global treasure hunt—but instead of gold, scientists are collecting viruses. That’s the Global Virome Project (GVP), conceived around 2015 to identify potential pandemic threats. Sounds noble? Maybe. But Thacker reveals emails showing the project was illegally funded through misdirected State Department money. Funds meant for the Predict program—a virus surveillance initiative—were funneled through UC Davis to EcoHealth Alliance, a nonprofit later banned by HHS for its ties to the Wuhan Institute of Virology.

EcoHealth Alliance isn’t just any nonprofit. They became infamous for subcontracting gain-of-function research to Wuhan, China—research controversially backed by Dr. Anthony Fauci. Thacker highlights how this “nonprofit” acted as a financial pipeline, diverting public funds into risky experiments with minimal oversight.

Remember when Fauci insisted COVID-19 wasn’t lab-made? Thacker isn’t buying it. He points to Fauci’s role in funding gain-of-function studies (enhancing viruses to study their spread) and the Proximal Origins paper in Nature Medicine, which dismissed the lab-leak theory. Congressional hearings later caught Fauci in contradictions, with Senator Rand Paul accusing him of lying under oath.

Thacker pulls no punches: “Fauci’s a pathological liar.” He argues Fauci’s shifting narratives on COVID origins, masks, and lockdowns were less about science and more about covering tracks. Why? To protect the NIH’s reputation—and possibly his own.

What happens when a child dies during a vaccine trial? According to Thacker, Pfizer didn’t shout it from the rooftops. Alex Berenson uncovered a Pfizer clinical trial document reporting a child’s death listed as an “adverse event.” Yet outlets like Public Citizen—traditionally critical of Big Pharma—stayed silent. Thacker asks: “Since when do we ignore safety for speed?”

Why did mainstream media downplay vaccine risks? Thacker ties it to cozy relationships with pharma advertisers and government pressure. He compares journalists to “cicadas”—only loud when politically convenient.

While the CDC frets over hypothetical pandemics, chronic diseases like obesity and heart disease kill millions annually. Thacker argues public health agencies chase headlines (and funding) by hyping rare threats while ignoring everyday killers. “Why pour billions into virus hunting when we know what’s killing us today?”

Thacker drops a bombshell: The CIA once planted agents as New York Times reporters abroad. This historical tidbit underscores his broader point—media often serves power, not truth. Today, NGOs like GIJN (Global Investigative Journalism Network) lobby for government funds while avoiding scrutiny of their own backers.

Ever heard of Matthew Ty? Thacker describes how Chinese state media cloned an American journalist’s likeness to spread propaganda. It’s a wild example of how misinformation thrives when journalists prioritize access over accountability.

Thacker compares EcoHealth Alliance to the Clinton Foundation—a “nonprofit” blurring lines between public service and private gain. Both funneled money through opaque channels, with minimal transparency.

Remember the laptop scandal? Thacker notes evidence of foreign funds flowing to Biden family accounts, asking, “Why pardon someone unless there’s something to hide?” He ties this to broader patterns of NGOs acting as money-laundering fronts.

Thacker leans heavily on the lab-leak theory, citing Australian intel sources and cremation data suggesting COVID spread earlier than reported. He critiques the WHO’s China-friendly investigation as a “BBQ that got out of control.”

A declassified CIA report under Biden claimed “low confidence” in the lab-leak theory—but Thacker suspects political meddling. “If Trump’s team knew it was a bioweapon, no wonder they panicked,” he muses.

Thacker slams lockdowns as unscientific overreach, comparing them to using a flamethrower to light a candle. He highlights how China’s harsh measures sparked riots, while the U.S. ignored chronic health trade-offs (e.g., addiction spikes).

A coalition of state attorneys general recently demanded Congress investigate Fauci. Thacker hopes this sparks accountability but doubts DC’s “old boys’ club” will allow it.

Thacker’s solution? Redirect funds to chronic diseases, break up bureaucratic monopolies like the NIH, and enforce transparency in research funding.

Public health should heal—not hide. From illegal virus hunting to media collusion, Thacker’s revelations paint a system corrupted by money and power. Until we prioritize people over politics, the next pandemic might be one of trust.

A virus-collection initiative funded by misdirected State Department money, later linked to gain-of-function research in Wuhan.

They funneled U.S. taxpayer dollars to the Wuhan Institute of Virology and were banned by HHS for lack of oversight.

Thacker argues Fauci misled Congress about NIH-funded research in Wuhan, citing the Proximal Origins paper as evidence.

Outlets avoided criticizing pharma advertisers, while NGOs with government ties suppressed adverse event reports.

Satellite data showing unusual hospital activity near Wuhan in late 2019 and intel sources pointing to lab accidents.